Propecia Information
Pharmacology:
Propecia Finasteride is a competitive and specific inhibitor of Type II 5 alpha-reductase, an intracellular enzyme that converts the androgen testosterone into dihydrotestosterone (DHT). Two distinct isozymes of 5 alpha-reductase are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5 alpha-reductase is predominant in the sebaceous glands of most regions of skin, including scalp and liver. Type I 5 alpha-reductase is responsible for approximately one-third of circulating DHT. The Type II 5 alpha-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.
Does PROPECIA really work?
Based on vertex studies at 24 months of men 18 to 41 with mild to moderate hair loss, the clinical results of PROPECIA are impressive:
83% maintained their hair based on hair count (vs. 28% with placebo), 66% had visible regrowth as rated by independent dermatologists (vs. 7% with placebo), 80% were rated as improved by clinical doctors (vs. 47% with placebo), and most men reported an increase in the amount of hair, a decrease in hair loss, and improvement in appearance.
Only a doctor can determine if PROPECIA is right for you. PROPECIA is for men only. Further, women who are or may potentially be pregnant must not use PROPECIA and should not handle crushed or broken tablets because it may cause abnormalities of a male baby’s sex organs. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling.
What should I discuss with my healthcare provider before taking Propecia?
* Before taking this medication, tell your doctor if you have liver disease. You may not be able to take Propecia, or you may need a lower dose or special monitoring during treatment.
* Propecia is intended for use by men only.
* Propecia is not indicated for use by women.
No Comments
No comments yet.
Sorry, the comment form is closed at this time.